TrialThe international journal of neuropsychopharmacology2016

A Phase II Dose-Ranging Study Evaluating the Efficacy and Safety of the Orexin Receptor Antagonist Filorexant (MK-6096) in Patients with Primary Insomnia.

Kathryn M Connor et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.